# Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct03977233/  
OnCo record `nct03977233` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), irinotecan (and liposomal irinotecan) and fluorouracil (5-FU) in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.

## Summary

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT03977233 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 45 participants, started 2019-06-12 and due to reach its primary completion in 2027-07. Interventions recorded: Oxaliplatin; Leucovorin; Irinotecan Hydrochloride; 5-FU. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma; Pancreatic Neoplasms; Pancreatic Cancer Non-resectable; Pancreatic Cancer Resectable. Primary outcome: Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT03977233
- Phase: 2
- Setting: Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer
- Sponsor: UNC Lineberger Comprehensive Cancer Center
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT03977233: https://clinicaltrials.gov/study/NCT03977233

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03977233.json